• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.

作者信息

Arora Sankalp, Vachhani Pankit, Bachiashvili Kimo, Jamy Omer

机构信息

Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

出版信息

Leuk Lymphoma. 2021 Sep;62(9):2292-2294. doi: 10.1080/10428194.2021.1897807. Epub 2021 Mar 10.

DOI:10.1080/10428194.2021.1897807
PMID:33691573
Abstract
摘要

相似文献

1
Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.维奈托克联合化疗用于复发/难治性早期T细胞前体急性淋巴细胞白血病
Leuk Lymphoma. 2021 Sep;62(9):2292-2294. doi: 10.1080/10428194.2021.1897807. Epub 2021 Mar 10.
2
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.维奈托克与地西他滨治疗难治性TP53突变的早期T细胞前体急性淋巴细胞白血病
Ann Hematol. 2022 Mar;101(3):697-699. doi: 10.1007/s00277-021-04530-y. Epub 2021 May 6.
3
[Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].维奈托克联合多药化疗治疗15例复发或难治性早期T细胞前体急性淋巴细胞白血病的临床疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):649-653. doi: 10.3760/cma.j.issn.0253-2727.2023.08.006.
4
Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.维奈托克联合地西他滨及HAAG方案：复发/难治性T细胞急性淋巴细胞白血病的一种新型挽救策略
Ann Hematol. 2022 Nov;101(11):2525-2528. doi: 10.1007/s00277-022-04912-w. Epub 2022 Sep 5.
5
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.维奈托克联合阿扎胞苷作为复发或难治性T细胞急性淋巴细胞白血病的一种有效且安全的挽救方案：病例系列
Leuk Lymphoma. 2021 Dec;62(13):3300-3303. doi: 10.1080/10428194.2021.1957876. Epub 2021 Jul 29.
6
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.维奈克拉联合HAG方案挽救了复发/难治性早期T细胞前体急性淋巴细胞白血病。
Ann Hematol. 2020 Feb;99(2):395-397. doi: 10.1007/s00277-019-03902-9. Epub 2019 Dec 26.
7
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Venetoclax 联合化疗治疗复发或难治性 T 细胞急性淋巴细胞白血病的临床经验。
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):212-218. doi: 10.1016/j.clml.2019.09.608. Epub 2019 Sep 30.
8
Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.维奈托克与地西他滨治疗儿童难治性T细胞淋巴母细胞淋巴瘤
J Pediatr Hematol Oncol. 2021 Oct 1;43(7):e991-e996. doi: 10.1097/MPH.0000000000002050.
9
Venetoclax use in a patient with ataxia telangiectasia and early T-cell precursor acute lymphoblastic leukemia.维奈托克在一名患有共济失调毛细血管扩张症和早期T细胞前体急性淋巴细胞白血病患者中的应用。
Pediatr Blood Cancer. 2024 Aug;71(8):e31123. doi: 10.1002/pbc.31123. Epub 2024 Jun 5.
10
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.维奈托克和纳武利尤单抗联合化疗治疗复发或难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤患者。
Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16.

引用本文的文献

1
Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.维奈托克与阿扎胞苷联合高三尖杉酯碱、阿糖胞苷和阿柔比星用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗。
Int J Hematol. 2025 Apr;121(4):547-552. doi: 10.1007/s12185-025-03915-3. Epub 2025 Jan 23.
2
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.达雷妥尤单抗、维奈克拉、阿扎胞苷和地塞米松联合治疗使一名经过大量前期治疗且化疗难治的早期T前体急性淋巴细胞白血病/淋巴瘤患者获得完全缓解。
Ann Hematol. 2025 Jan;104(1):829-833. doi: 10.1007/s00277-024-06118-8. Epub 2025 Jan 23.
3
Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.西达本胺和维奈克拉通过MYCN/DKK3在B细胞急性淋巴细胞白血病中协同调节Wnt/β-连环蛋白信号通路。
Ann Hematol. 2025 Jan;104(1):489-501. doi: 10.1007/s00277-024-06110-2. Epub 2024 Nov 28.
4
Editorial: Immunotherapy in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).社论：急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）中的免疫疗法。
Front Immunol. 2024 Oct 17;15:1501760. doi: 10.3389/fimmu.2024.1501760. eCollection 2024.
5
[Chinese expert consensus on diagnosis and treatment of adult early T cell precursor acute lymphoblastic leukemia (2023)].《成人早期T细胞前体急性淋巴细胞白血病诊断与治疗中国专家共识（2023年版）》
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):977-982. doi: 10.3760/cma.j.issn.0253-2727.2023.12.002.
6
Novel Biomarkers and Molecular Targets in ALL.急性淋巴细胞白血病的新型生物标志物和分子靶点。
Curr Hematol Malig Rep. 2024 Feb;19(1):18-34. doi: 10.1007/s11899-023-00718-3. Epub 2023 Dec 4.
7
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.维奈克拉联合 CAG 方案治疗早幼粒细胞性急性淋巴细胞白血病 1 例报告并文献复习
Int J Hematol. 2023 Oct;118(4):483-488. doi: 10.1007/s12185-023-03623-w. Epub 2023 Jun 3.
8
Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey.维奈托克在波兰儿科血液肿瘤中心的应用：2022年调查
Children (Basel). 2023 Apr 19;10(4):745. doi: 10.3390/children10040745.
9
Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation.接受异基因造血干细胞移植的ETP-ALL/LBL患者与非ETP-ALL患者的特征及结局比较。
Front Oncol. 2023 Jan 4;12:1025885. doi: 10.3389/fonc.2022.1025885. eCollection 2022.
10
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.维奈托克为基础的治疗方案在急性淋巴细胞白血病中的新作用。
Int J Mol Sci. 2022 Sep 19;23(18):10957. doi: 10.3390/ijms231810957.